Logo

GUTS

Fractyl Health, Inc. Common Stock

GUTS

Fractyl Health, Inc. Common Stock • NASDAQ
$1.57 ▲ 6.08% (+0.09)
Market Cap $113.34 M
52w High $3.03
52w Low $0.82
Dividend Yield 0%
P/E -0.68
Volume 1.59M
Outstanding Shares 72.19M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $22.404M ▼ $-45.603M ▼ 0% $-0.71 ▼ $-45.313M ▼
Q2-2025 $0 $26.079M ▲ $-27.889M ▼ 0% $-0.57 ▼ $-25.809M ▼
Q1-2025 $0 ▼ $24.759M ▼ $-23.735M ▲ 0% ▲ $-0.49 ▲ $-24.469M ▲
Q4-2024 $3K ▼ $25.213M ▲ $-24.97M ▼ -832.333K% ▼ $-0.51 ▼ $-24.987M ▼
Q3-2024 $14K $23.801M $-23.173M -165.521K% $-0.48 $-23.585M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $77.657M ▲ $114.272M ▲ $117.45M ▲ $-3.178M ▲
Q2-2025 $22.291M ▼ $62.006M ▼ $80.218M ▲ $-18.212M ▼
Q1-2025 $42.108M ▼ $83.04M ▼ $76.665M ▼ $6.375M ▼
Q4-2024 $67.464M ▼ $108.077M ▼ $79.653M ▲ $28.424M ▼
Q3-2024 $84.664M $126.924M $76.602M $50.322M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-45.603M ▼ $-22.714M ▼ $-8K ▲ $78.088M ▲ $55.366M ▲ $-22.722M ▼
Q2-2025 $-27.889M ▼ $-21.199M ▲ $-98K ▲ $1.48M ▲ $-19.817M ▲ $-21.297M ▲
Q1-2025 $-23.735M ▲ $-25.079M ▼ $-448K ▼ $171K ▲ $-25.356M ▼ $-25.527M ▼
Q4-2024 $-24.97M ▼ $-17.034M ▲ $-233K ▼ $67K ▼ $-17.2M ▲ $-17.267M ▲
Q3-2024 $-23.173M $-18.039M $-213K $162K $-18.09M $-18.252M

Five-Year Company Overview

Income Statement

Income Statement Fractyl Health is still a pure development-stage company: it has no product sales yet and only expenses. The income statement shows a steady pattern of research and operating costs, which translate into recurring losses each year. These losses have been fairly consistent in size relative to the company, reflecting an ongoing investment phase rather than any sign of commercial maturity. This profile is typical of early biotech: spending heavily today on science and clinical work in hopes of future approvals, with no revenue yet to offset those costs.

Balance Sheet

Balance Sheet The balance sheet is small and relatively simple. Assets are modest and largely made up of cash, with very little tied up in physical equipment. Debt has been meaningful compared with the company’s size, but recent improvements in equity suggest fresh capital has come in, likely linked to the listing and financing activities. Historically, the company operated with a thin or even negative equity base, which underlines how dependent it has been on external funding. Overall, it has some cash to work with but not a deep financial cushion, and the balance sheet is clearly built for a company still in the lab and clinical phase, not yet in full commercialization mode.

Cash Flow

Cash Flow Cash flows show a straightforward story: money consistently flows out to fund research, clinical trials, and operations, with nothing coming in from product sales. Operating cash burn has been steady, and there is essentially no spending on large physical assets, which means nearly all cash goes into people, trials, and technology rather than factories or facilities. Management’s stated cost-cutting and refocusing efforts are aimed at stretching this cash for a few more years, but unless successful products emerge, the business will likely need future fundraising to support later-stage trials and any eventual launch activities.

Competitive Edge

Competitive Edge Fractyl is trying to carve out a distinct position in one of the most competitive areas in healthcare: obesity and type 2 diabetes. Its focus is different from mainstream drug makers that sell injectable weight-loss and diabetes drugs. Instead, Fractyl is targeting the root biological mechanisms in the gut and pancreas using a device-based procedure and gene therapies. This offers a potential edge if the company can show that its treatments provide lasting benefits and act as an “off-ramp” from chronic drugs like GLP-1s. The company’s patent portfolio and head start in this niche are positives. On the other hand, it is competing against giant pharmaceutical companies with deep resources, and it still must prove its approach in late-stage trials and navigate strict regulatory reviews. Clinical outcomes over the next few years will be critical in determining whether this scientific and strategic differentiation translates into a durable competitive position.

Innovation and R&D

Innovation and R&D Innovation is the core of Fractyl’s story. The Revita procedure aims to reset the lining of the small intestine to improve metabolic signaling, while the Rejuva platform is designed to deliver one-time gene therapies to the pancreas so the body can make its own beneficial hormones over the long term. This combination of endoscopic intervention and targeted gene therapy is unusual, and backed by a large patent estate and early human and animal data that the company describes as encouraging. The pipeline, however, is still relatively early. Key human data for weight maintenance and the first gene therapy candidates are several years away, and the company has already had to narrow its focus to stretch its resources. This creates both significant upside potential if the science works and high execution and clinical risk if results disappoint or timelines slip.

Summary

Fractyl Health is an early-stage biotech focused on rethinking how obesity and type 2 diabetes are treated, aiming at the underlying biology in the gut and pancreas rather than just managing symptoms with chronic drugs. Financially, it is a classic development-stage company: no revenue, steady losses, modest cash reserves, and a clear reliance on external funding to advance its programs. Strategically, its two main platforms—Revita and Rejuva—offer a differentiated, potentially long-lasting treatment approach in a huge disease area, backed by patents and early data, but still facing a long path through trials and regulators. The company’s future will hinge on a few key clinical readouts and its ability to maintain funding and focus until those results are known, making it a high-uncertainty, high-dependency story typical of cutting-edge biotech.

NEWS

November 12, 2025 · 4:05 PM UTC

Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027

Read more

November 5, 2025 · 7:00 AM UTC

Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

Read more

October 7, 2025 · 7:00 AM UTC

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

Read more

September 26, 2025 · 7:05 AM UTC

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

Read more

September 26, 2025 · 7:00 AM UTC

Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation

Read more